Crinetics Pharmaceuticals, Inc.
NASDAQ:CRNX · NASDAQ Global Select
-$0.22 today
Vol 1.49M · Avg 1.19M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-46.9%
avg -5.9%
ROIC
-48.9%
avg -41.2%
ROA
-41.0%
avg -37.3%
Analysis
ROA is currently the strongest return metric at -41.0% versus its period average of -37.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
R. Scott Struthers | Founder, President, Chief Executive Officer & Director | $1.19M | — | 64 | $515,878.00 | 0.49% |
Tobin C. Schilke | Chief Financial Officer | $1.02M | — | 51 | $78,121.00 | 0.07% |
Stephen F. Betz | Co-Founder & Chief Scientific Officer | $755,150.00 | — | 60 | $141,342.00 | 0.13% |
Alan S. Krasner | Chief Endocrinologist | $653,924.00 | — | 63 | $153,473.00 | 0.15% |
Kea Lingo | Chief Information Officer | — | — | — | — | — |
Kevin Capps | Head of Intellectual Property | — | — | — | — | — |
Adriana Cabre | Chief Human Resources Officer | — | — | — | — | — |
Gayathri Diwakar | Senior Director of Investor Relations | — | — | — | — | — |
Chris Robillard | Chief Business Officer | — | — | — | — | — |
Garlan Adams | Chief Legal Officer & Corporate Secretary | — | — | — | — | — |
Robert Cuddihy | Senior Vice President of Medical Affairs | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
21
$8.51M
Net Sentiment
$8.51M
Net selling
Most Active
Pizzuti Dana
7 transactions
1–10 of 21
Analysis
Insiders reported 0 buys worth $0.00 and 21 sells worth $8.51M over the last 12 months. That adds up to net selling of $8.51M. Pizzuti Dana was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -67.4% | +171.8% (10yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -67.4% over three years. Forward estimates point to Revenue at +171.8% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.43B
Immunovant, Inc.
NASDAQ:IMVT
$7.19B
Praxis Precision Medicines, Inc.
NASDAQ:PRAX
$5.88B
Akero Therapeutics, Inc.
AKRO
$4.50B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.17B
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
$3.67B
Viking Therapeutics, Inc.
NASDAQ:VKTX
$3.56B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.51B
Dyne Therapeutics, Inc.
NASDAQ:DYN
$3.25B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Who manages CRNX?
Crinetics Pharmaceuticals, Inc. (CRNX) lists 11 active executives. The top listed executive is Alan S. Krasner, Chief Endocrinologist.
Are CRNX insiders buying or selling?
Recent insider activity shows net buying of $16.53M.
Explore More
Continue the stock analysis
Jump to another research area for this company.